Redcare Pharmacy’s Investor Confidence Crisis Defies a Strong Operational Rebound

The disconnect between Redcare Pharmacy’s operational performance and its stock price has rarely been starker. While the online pharmacy delivered a robust 18% revenue surge in the first quarter of 2026, its shares have cratered by roughly 30% since the start of the year, closing at just €46.02. That leaves the stock trading at a fraction of its 52-week high of nearly €129, a brutal repricing that analysts argue has overshot the company’s fundamentals.

Revenue Growth Accelerates, But Margins Remain Under Scrutiny

Group revenue climbed to €849.5 million in the first three months of 2026, comfortably exceeding the company’s own full-year growth forecast. The net loss narrowed to €10.5 million, a marked improvement from the prior quarter, though the business remains in the red on a rolling twelve-month basis.

The earnings picture, however, is more nuanced. The gross margin came under pressure from fierce competition in the over-the-counter (OTC) segment and a rising share of prescription drugs, which carry thinner margins. Efficiency gains in marketing spend and fixed-cost scaling partially offset the drag. The adjusted EBITDA margin improved to 1.7%, narrowly missing the roughly 2% analysts had penciled in.

Non-Prescription Business Regains Momentum

A particularly encouraging sign emerged in the high-margin OTC business. After a period of sluggish growth, German non-prescription sales accelerated to 9% in the first quarter, up from just 5% in the prior quarter. Early trading data for April points to further improvement, with growth running at around 11%. This matters because OTC products generate significantly higher margins than the fast-growing prescription segment, where Redcare continues to dominate with a 67% online market share.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

The resurgence comes despite aggressive moves by brick-and-mortar rivals like dm and Rossmann into the online pharmacy space. Rossmann’s new digital offering, notably, does not include prescription drugs, preserving a key competitive moat for Redcare. The company’s prescription business in Germany surged 55% in the quarter, reinforcing its leadership position.

Structural Tailwinds and Strategic Investments

The ongoing consolidation of Germany’s pharmacy network provides a powerful structural tailwind. By the end of 2025, the number of physical pharmacies had shrunk to just over 16,600 locations. Each closure potentially funnels more prescription volume into digital channels, where Redcare is the dominant player.

To capture this flow, the company is investing heavily in infrastructure. A new logistics hub in Pilsen, Czech Republic, along with automation upgrades at its main site in Sevenum, are designed to boost annual capacity by 15 million packages. Management has flagged 2025 and 2026 as peak investment years, which has weighed on near-term profitability. Cash holdings fell to €135 million by the end of March, primarily due to the repayment of a convertible bond.

Redcare Pharmacy at a turning point? This analysis reveals what investors need to know now.

Analyst Optimism vs. Market Reality

Despite the share price rout, the analyst community remains broadly bullish. Nine out of ten analysts covering the stock rate it a buy, with a consensus price target of roughly €95. Even the most bearish estimate of €54 sits comfortably above the current trading level. Jefferies has reiterated a buy rating with a €150 target, praising the strong start to the year.

The critical test for management now lies in delivering on its full-year guidance. Redcare is targeting at least 2.5% adjusted EBITDA margin for 2026, alongside double-digit revenue growth. Achieving the €670 million revenue target for the German prescription business would likely reignite the valuation debate. New CFO Hendrik Krampe faces the task of convincing investors that the heavy logistics spending will translate into sustainable profitability, not just top-line expansion.

Ad

Redcare Pharmacy Stock: New Analysis - 8 May

Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Redcare Pharmacy analysis...

en | NL0012044747 | REDCARE | boerse | 69292174 |